Cargando…
Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year
AIMS: Dapagliflozin and exenatide reduce body weight by differing mechanisms. Dual therapy with these agents reduces body weight, adipose tissue volume, glycaemia and systolic blood pressure (SBP) over 24 weeks. Here, we examined these effects over 1 year in obese adults without diabetes. MATERIALS...
Autores principales: | Lundkvist, Per, Pereira, Maria J., Katsogiannos, Petros, Sjöström, C. David, Johnsson, Eva, Eriksson, Jan W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575470/ https://www.ncbi.nlm.nih.gov/pubmed/28345814 http://dx.doi.org/10.1111/dom.12954 |
Ejemplares similares
-
Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes
por: Lundkvist, Per, et al.
Publicado: (2016) -
A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss
por: Pereira, Maria J., et al.
Publicado: (2018) -
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION‐8 randomized controlled trial
por: Frías, Juan P., et al.
Publicado: (2018) -
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION‐8 study
por: Jabbour, Serge A., et al.
Publicado: (2018) -
Once-Weekly Exenatide in Youth With Type 2 Diabetes
por: Tamborlane, William V., et al.
Publicado: (2022)